The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
about
How to assess gay, bisexual and other men who have sex with men for chemsex.Symptoms and signs in interpreting gamma-hydroxybutyrate (GHB) intoxication - an explorative study.Management of Gamma-Butyrolactone Dependence with Assisted Self-Administration of GBL.The neurobiology of alcohol consumption and alcoholism: an integrative historyNovel psychoactive substances of interest for psychiatry.Baclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study.GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboonsNutrition of the critically ill — a 21st-century perspective.Outpatient treatment of acute poisoning by substances of abuse: a prospective observational cohort study.Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): time course and severity of withdrawal in baboons.Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity.Nutrition of the critically ill - emphasis on liver and pancreasScreening and confirmation methods for GHB determination in biological fluids.Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway.Pharmacologic, Pharmacokinetic, and Clinical Assessment of Illicitly Used γ-Hydroxybutyrate.Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.The outcome of agitation in poisoned patients in an Iranian tertiary care university hospitalIntoxication with GHB/GBL: characteristics and trends from ambulance-attended overdoses.GHB for cataplexy: Possible mode of action.Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial.Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression.Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial.Evolving P450pyr monooxygenase for highly regioselective terminal hydroxylation of n-butanol to 1,4-butanediol.
P2860
Q30251538-A22E042C-A22D-4A75-9D56-BC975F385FBAQ33575947-97F3E3E0-0B10-43DC-8099-3DF4E5B90DACQ33904143-91112389-3A13-430C-9FAB-F5A25029F206Q34378869-40D9B3E3-5ABA-42EB-B5DE-1FC8E0B66695Q34667835-D4DBEB52-307D-4E39-8842-8017231D73D7Q35583885-49A69D12-28AE-494A-A01B-9488AE440EB6Q35710620-42B5CD42-D523-4E48-935C-C470D8FF5B12Q36072485-60967D4D-6280-46C0-87A8-415FDAE655B8Q36231851-3C582497-3C08-4FE9-B60C-EDE3C820A90FQ36539839-06FC06ED-D3E9-49CE-95C0-8AB165568919Q36607663-B64294A7-E903-47DE-ADF9-D4F31F664EC9Q36923385-81F4C279-D3D5-48A5-9233-681C3ABA63BEQ37033882-9D0F1574-E6F1-44CA-8108-CF2E005C0345Q37224304-533D6EC0-24F1-4EE9-BB10-F5FA56C598FCQ37584566-795FDDF1-EFB8-46CB-B468-8EE376E2A6CBQ38185603-D57278D8-5158-4F88-B828-65FC39E2C37AQ38838767-8C3F726C-8AFD-42C5-8DB5-822B406435A7Q38838821-AC92E945-2040-42F8-9421-C764962349B1Q39048315-CCC7D578-6B86-4A1E-9C89-8E0F6A313A7EQ41462770-2AA7FE31-BD2D-4E89-B77D-EB0F73387B9AQ41639858-2F91D87A-E2C9-4303-913B-FEA5D1BFEF70Q42183368-571F5A4C-9717-4780-8978-BD4D2A1FC354Q47734007-704DFA66-48AA-4D4D-AE4E-78637318B96FQ47752026-8CABDB01-D647-4170-8324-B2433B372A86Q47841359-7E8D5122-6A4A-418F-A0B2-04D5E90913BEQ52317686-1F9B66AB-5E45-429D-8C3C-EBDA4C609DE0Q53382461-E53AFDA4-0CD5-489F-941F-7A45C95EE8CF
P2860
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@ast
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@en
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@nl
type
label
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@ast
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@en
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@nl
prefLabel
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@ast
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@en
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@nl
P2093
P2860
P1433
P1476
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
@en
P2093
J Allister Vale
Kai Knudsen
Leo J Schep
P2860
P304
P356
10.3109/15563650.2012.702218
P407
P577
2012-07-01T00:00:00Z